Records containing: Neuroendocrine Tumors
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-02-05Establishment of a Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department
-
CLINICAL_TRIALS study record update · 2026-02-05A Prospective Randomized Phase II Study Assess the Schema of Retreatment With Lutathera® ([177LU]LU-DOTA-TATE) in Patients With New Progression of Intestinal Well-differenciated Neuroendocrine Tumor
-
CLINICAL_TRIALS study record update · 2026-01-29A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 (CDH17) Chimeric Antigen Receptor (CAR) T Cell Therapy for the Treatment of Relapsed or Refractory Gastrointestinal Cancers
-
CLINICAL_TRIALS study record update · 2026-01-27A Phase 1b, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics of Sapu003 in Advanced mTOR-sensitive Solid Tumors (With or Without Exemestane)
-
CLINICAL_TRIALS study record update · 2026-01-26A Study to Explore the Safety, Tolerability, and Preliminary Efficacy of NEUK203-13 Injection in Patients With Neuroendocrine Tumors Who Have Failed Systemic Therapy
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-01-23A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers
-
CLINICAL_TRIALS study record update · 2026-01-22Integrated Cancer Repository for Cancer Research
-
CLINICAL_TRIALS study record update · 2026-01-15Influence of Tumour and Patient's Related Factors on the Response to Medical Treatments in Well Differentiated GEP-NENs
-
CLINICAL_TRIALS study record update · 2026-01-14A Phase II Assessment of the Safety and Efficacy of TheraSphere® Selective Internal Radiation Therapy (SIRT) in the Treatment of Metastatic (Liver) Neuroendocrine Tumours (NETs)
-
CLINICAL_TRIALS study record update · 2026-01-14PELICAN: a Phase II Study of Etoposide-carboplatin Chemotherapy in Combination With Pembrolizumab and Lenvatinib Maintenance in Advanced High-grade Neuroendocrine Tumours (HG-NETs)
-
CLINICAL_TRIALS study record update · 2026-01-14An International Multicentre Randomized Unblinded Phase II Study Comparing Adjuvant Treatment With 177Lu-DOTATATE (Lutathera®) to Best Supportive Care in Patients After Resection of Neuroendocrine Liver Metastases
-
CLINICAL_TRIALS study record update · 2025-12-29Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms
-
CLINICAL_TRIALS study record update · 2025-12-23A Phase II, Open-label Study of CVM-1118 Administered Orally to Patients With Advanced Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-12-23International, Non-interventional, Post-Authorization Long-Term Safety Study of Lutathera, in Patients With Unresectable or Metastatic, Well-Differentiated, Somatostatin Receptor Positive, Gastroenteropancreatic Neuroendocrine Tumours
-
CLINICAL_TRIALS study record update · 2025-12-19Prospective Multicenter Real-world Study of Surufatinib in Patients With Advanced Neuroendocrine Neoplasms
-
CLINICAL_TRIALS study record update · 2025-12-18A Cohort Study of Symptom Burden and Therapeutic Selection in Neuroendocrine Tumors (NETs)
-
CLINICAL_TRIALS study record update · 2025-12-18A Phase II, Multi-Cohort Trial of Combination Nivolumab and Temozolomide in Recurrent/Refractory Small-Cell Lung Cancer and Advanced Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-12-17A Phase 1 Trial of the Oncolytic Virus SVV-001 in Combination With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas or Well-Differentiated High-Grade (Grade 3) Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-12-10UPCC 04219 Phase 2 Study of Capecitabine-Temozolomide(CapTem) With Yttrium-90 Radioembolization in the Treatment of Patients With Unresectable Metastatic Grade 2/3 Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-12-08Prospective Pilot Study Assessing Imaging Performance of 89Zirconium-labelled Girentuximab (89Zr-TLX250) PET-CT in Patients With HepatoCellular Carcinoma, IntraHepatic CholangioCarcinoma or Gastro-Entero-Pancreatic Neuroendocrine Neoplasms
-
CLINICAL_TRIALS study record update · 2025-12-03A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-12-03GU-187: Phase II Trial of Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma and Neuroendocrine Tumors
-
CLINICAL_TRIALS study record update · 2025-11-24The Epigenetic Modification of Somatostatin Receptor-2 to Improve Therapeutic Outcome With Lutathera in Patients With Metastatic Neuroendocrine Tumours.
-
CLINICAL_TRIALS study record update · 2025-11-21MGMT-NET: O6-methylguanine-DNA Methyltransferase (MGMT) Status in Neuroendocrine Tumors: Predictive Factor of Response to Alkylating Agents
-
CLINICAL_TRIALS study record update · 2025-11-17Lesion-to-lesion Comparison of 68Ga-HA-DOTATATE, 18F-DOPA, and 18F-FDG PET/CT in the Evaluation of Metastatic Neuroendocrine Tumors